iShares Bitcoin Trust vs Zoetis Inc — how do they compare? iShares Bitcoin Trust trades at $46.71 (market cap $67.31B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: iShares Bitcoin Trust is far larger — about 2.2× Zoetis Inc's market cap, and Zoetis Inc pays a 2.9% dividend while iShares Bitcoin Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and Zoetis Inc for 70 Days on average.
| IBIT | ZTS | |
|---|---|---|
Market Cap | $67.31B | $30.20B |
Volume | 56,154,544 | 6,175,327 |
Sector | Crypto-linked | Health |
52-Week High | $68.74 | $147.53 |
52-Week Low | $33.29 | $69.09 |
Typical Hold Time | 40 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $46.79, down 0.89% with bearish technical signals from oscillators and mixed moving averages. Recent news highlights significant institutional inflows, including a $196 million single-day inflow on October 1, 2026. The stock faces resistance at $47-$48 with support at $44-$46, while RSI levels suggest potential oversold conditions. Financial ratios remain undisclosed in current data.
Outlook hinges on sustained institutional interest amid volatile ETF flows, with Q3 inflows reversing prior outflows. Risks include fee structures impacting returns and market sentiment shifts. Upside potential exists if Bitcoin ETF momentum continues, but investors face exposure to crypto market volatility without direct cash flow benefits.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →